However, a CD27 agonizing monoclonal antibody, varlilumab, has been extensively studied both in in vitro and in vivo in phase I/II clinical trials for a number of hematologic and solid tumor types, including Hodgkin’s lymphoma, non-Hodgkin’s lymphoma (NHL), glioblastoma, melanoma, renal cell carcinoma, prostate adenocarcinoma, colorectal adenocarcinoma, and ovarian cancer (57–60). The gene discussed is CD27; the disease is colorectal adenocarcinoma.